These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7639273)

  • 1. Platelet von Willebrand factor abnormalities in myeloproliferative syndromes.
    Castaman G; Lattuada A; Ruggeri M; Tosetto A; Mannucci PM; Rodeghiero F
    Am J Hematol; 1995 Aug; 49(4):289-93. PubMed ID: 7639273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients.
    Castaman G; Rodeghiero F; Lattuada A; La Greca G; Mannucci PM
    Am J Hematol; 1993 Dec; 44(4):266-9. PubMed ID: 8237998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraplatelet levels of vWF:Ag and fibrinogen in myeloproliferative disorders.
    Meschengieser S; Blanco A; Woods A; Maugeri N; Fernandez J; Dupont J; Lazzari MA
    Thromb Res; 1987 Nov; 48(3):311-9. PubMed ID: 3501618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders.
    Tatewaki W; Takahashi H; Shibata A
    Clin Lab Haematol; 1988; 10(4):417-25. PubMed ID: 3150698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.
    Rottenstreich A; Kleinstern G; Krichevsky S; Varon D; Lavie D; Kalish Y
    Eur J Intern Med; 2017 Jun; 41():49-54. PubMed ID: 27919526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia.
    Janjetovic S; Rolling CC; Budde U; Schneppenhem S; Schafhausen P; Peters MC; Bokemeyer C; Holstein K; Langer F
    Thromb Res; 2022 Oct; 218():35-43. PubMed ID: 35988442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.
    Lancellotti S; Dragani A; Ranalli P; Petrucci G; Basso M; Tartaglione R; Rocca B; De Cristofaro R
    J Thromb Haemost; 2015 Jul; 13(7):1226-37. PubMed ID: 25876231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis.
    Fabris F; Casonato A; Grazia del Ben M; De Marco L; Girolami A
    Br J Haematol; 1986 May; 63(1):75-83. PubMed ID: 3085704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A variant of type II von Willebrand disease with an abnormal triplet structure and discordant effects of protease inhibitors on plasma and platelet von Willebrand factor structure.
    Gralnick HR; Williams SB; McKeown LP; Maisonneuve P; Jenneau C; Sultan Y
    Am J Hematol; 1987 Mar; 24(3):259-66. PubMed ID: 3493688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma.
    van Genderen PJ; van Vliet HH; Prins FJ; van de Moesdijk D; van Strik R; Zijlstra FJ; Budde U; Michiels JJ
    Ann Hematol; 1997; 75(5-6):215-20. PubMed ID: 9433378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.
    Budde U; Scharf RE; Franke P; Hartmann-Budde K; Dent J; Ruggeri ZM
    Blood; 1993 Sep; 82(6):1749-57. PubMed ID: 8400231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type II H von Willebrand disease: new structural abnormality of plasma and platelet von Willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity.
    Federici AB; Mannucci PM; Lombardi R; Lattuada A; Colibretti ML; Dent JA; Zimmerman TS
    Am J Hematol; 1989 Dec; 32(4):287-93. PubMed ID: 2510503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet von Willebrand factor in Hermansky-Pudlak syndrome.
    McKeown LP; Hansmann KE; Wilson O; Gahl W; Gralnick HR; Rosenfeld KE; Rosenfeld SJ; Horne MK; Rick ME
    Am J Hematol; 1998 Oct; 59(2):115-20. PubMed ID: 9766795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal multimeric pattern of platelet von Willebrand factor (VWF) in a case of myelodysplastic syndrome (MDS) and its normalization in remission.
    deCataldo F; Baudo F; Redaelli R; Pezzetti L; Marenco P; Cattaneo D
    Am J Hematol; 1992 Feb; 39(2):151-2. PubMed ID: 1550109
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
    Shihong I; Morris D; Konkle BA
    Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Moake JL; McPherson PD
    Am J Med; 1989 Sep; 87(3N):9N-15N. PubMed ID: 2486537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of the largest platelet-von Willebrand multimers in a patient with lactoferrin deficiency and a bleeding tendency.
    Parker RI; McKeown LP; Gallin JI; Gralnick HR
    Thromb Haemost; 1992 Mar; 67(3):320-4. PubMed ID: 1641822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.